Strategic Partnerships Opportunity to expand preclinical capabilities through collaboration with genomics tool providers and genotoxicity service specialists, leveraging Noble’s integrated in vitro and in vivo offerings to create end-to-end preclinical packages for biotech customers.

Genotoxicity Synergy Recent integrations and partnerships with KromaTiD position Noble to upsell combined genotoxicity analysis solutions, enabling customers to streamline discovery, safety assessment, and regulatory-ready data in a single ecosystem.

RSV and Disease Models Proven capability with cotton rat RSV models and other animal disease models suggests cross-sell potential to clients developing vaccines and therapeutics targeting respiratory pathogens and related indications.

Regional Expertise Located in the BioHealth Capital Region with an experienced vivarium and preclinical team, Noble can target regional biotech startups and midsize CRO users seeking high-quality in vivo services and rapid study execution.

Full-Service Appeal As a CRO offering discovery to GLP-compliant preclinical studies, antibody production, tissue/animal sourcing, and study design, Noble can pitch bundled, scalable preclinical programs to accelerate customers from concept to clinic.